China Kanghui Holdings (NYSE: KH) and Obalon Therptcs (NASDAQ:OBLN) are both medical devices & implants companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.
This table compares China Kanghui Holdings and Obalon Therptcs’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|China Kanghui Holdings||N/A||N/A||N/A|
Earnings and Valuation
This table compares China Kanghui Holdings and Obalon Therptcs’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|China Kanghui Holdings||N/A||N/A||N/A||$0.72||N/A|
|Obalon Therptcs||$3.39 million||46.10||-$20.46 million||($1.99)||-4.50|
China Kanghui Holdings has higher revenue, but lower earnings than Obalon Therptcs. Obalon Therptcs is trading at a lower price-to-earnings ratio than China Kanghui Holdings, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and recommmendations for China Kanghui Holdings and Obalon Therptcs, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|China Kanghui Holdings||0||0||0||0||N/A|
Obalon Therptcs has a consensus price target of $13.67, indicating a potential upside of 52.53%.
Institutional & Insider Ownership
44.7% of Obalon Therptcs shares are held by institutional investors. 16.4% of Obalon Therptcs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
About China Kanghui Holdings
China Kanghui Holdings is a holding company and conducts all of its business through its two wholly owned subsidiaries in China, Changzhou Kanghui Medical Innovation Co., Ltd. (Changzhou Kanghui) and Beijing Libeier. The Company is a domestic developer, manufacturer and marketer of orthopedic implants in People’s Republic of China. The Company’s orthopedic implant brands are Kanghui and Libeier. It sells two lines of orthopedic implant products, trauma and spine. Its major trauma products, used in the surgical treatment of bone fractures, include a range of nails, plates and screws. Its major spine products, used in the surgical treatment of spine disorders, include screws, meshes, interbody cages and fixation systems. On July 31, 2008, we acquired 100% of the equity interests of Beijing Libeier. On July 31, 2009, the Company established Shanghai Zhikang Medical Devices Co., Ltd. (Shanghai Zhikang), which is wholly owned by Changzhou Kanghui.
About Obalon Therptcs
Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
What are top analysts saying about China Kanghui Holdings? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for China Kanghui Holdings and related companies.